[go: up one dir, main page]

WO2009032123A3 - Tetracyclic indole derivatives and their use for treating or preventing viral infections - Google Patents

Tetracyclic indole derivatives and their use for treating or preventing viral infections Download PDF

Info

Publication number
WO2009032123A3
WO2009032123A3 PCT/US2008/010147 US2008010147W WO2009032123A3 WO 2009032123 A3 WO2009032123 A3 WO 2009032123A3 US 2008010147 W US2008010147 W US 2008010147W WO 2009032123 A3 WO2009032123 A3 WO 2009032123A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
indole derivatives
tetracyclic indole
viral infections
preventing viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/010147
Other languages
French (fr)
Other versions
WO2009032123A2 (en
Inventor
Frank Bennett
Qingbei Zeng
Srikanth Venkatraman
Mousumi Sannigrahi
Kevin X Chen
Gopinadhan N Anilkumar
Stuart B Rosenblum
Joseph A Kozlowski
F George Njoroge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2008295483A priority Critical patent/AU2008295483B2/en
Priority to US12/675,277 priority patent/US20110104109A1/en
Priority to EP08795628A priority patent/EP2197884A2/en
Priority to CA2697451A priority patent/CA2697451A1/en
Priority to JP2010522933A priority patent/JP5179585B2/en
Priority to MX2010002316A priority patent/MX2010002316A/en
Application filed by Schering Corp filed Critical Schering Corp
Priority to CN200880113543A priority patent/CN101842376A/en
Publication of WO2009032123A2 publication Critical patent/WO2009032123A2/en
Publication of WO2009032123A3 publication Critical patent/WO2009032123A3/en
Priority to ZA2010/01391A priority patent/ZA201001391B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
PCT/US2008/010147 2005-07-13 2008-08-27 Tetracyclic indole derivatives and their use for treating or preventing viral infections Ceased WO2009032123A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/675,277 US20110104109A1 (en) 2005-07-13 2008-08-27 Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP08795628A EP2197884A2 (en) 2007-08-29 2008-08-27 Tetracyclic indole derivatives and their use for treating or preventing viral infections
CA2697451A CA2697451A1 (en) 2007-08-29 2008-08-27 Tetracyclic indole derivatives and methods of use thereof
JP2010522933A JP5179585B2 (en) 2007-08-29 2008-08-27 Tetracyclic indole derivatives and uses thereof
MX2010002316A MX2010002316A (en) 2007-08-29 2008-08-27 Tetracyclic indole derivatives and their use for treating or preventing viral infections.
AU2008295483A AU2008295483B2 (en) 2007-08-29 2008-08-27 Tetracyclic indole derivatives and their use for treating or preventing viral infections
CN200880113543A CN101842376A (en) 2007-08-29 2008-08-27 Tetracyclic indole derivatives and their use in treating or preventing viral infections
ZA2010/01391A ZA201001391B (en) 2007-08-29 2010-02-25 Tetracyclic indole derivatives and their use for treating or preventing viral infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96868407P 2007-08-29 2007-08-29
US60/968,684 2007-08-29

Publications (2)

Publication Number Publication Date
WO2009032123A2 WO2009032123A2 (en) 2009-03-12
WO2009032123A3 true WO2009032123A3 (en) 2009-06-11

Family

ID=40319417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010147 Ceased WO2009032123A2 (en) 2005-07-13 2008-08-27 Tetracyclic indole derivatives and their use for treating or preventing viral infections

Country Status (11)

Country Link
EP (1) EP2197884A2 (en)
JP (1) JP5179585B2 (en)
KR (1) KR20100061819A (en)
CN (1) CN101842376A (en)
AR (1) AR068109A1 (en)
AU (1) AU2008295483B2 (en)
CA (1) CA2697451A1 (en)
MX (1) MX2010002316A (en)
TW (1) TW200918536A (en)
WO (1) WO2009032123A2 (en)
ZA (1) ZA201001391B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063072B2 (en) 2009-09-21 2011-11-22 Roche Palo Alto Llc Heterocyclic antiviral compounds

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5501251B2 (en) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド (1-Azinone) substituted pyridoindoles as MCH antagonists
AR072088A1 (en) * 2008-06-13 2010-08-04 Schering Corp TRICYCLE INDOL DERIVATIVES AND THEIR METHODS OF USE
AU2009273327A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2334662A1 (en) 2008-09-26 2011-06-22 F. Hoffmann-La Roche AG Pyrine or pyrazine derivatives for treating hcv
KR20120011880A (en) 2009-04-25 2012-02-08 에프. 호프만-라 로슈 아게 Heterocyclic antiviral compounds
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
TWI428332B (en) 2009-06-09 2014-03-01 Hoffmann La Roche Heterocyclic antiviral compounds
WO2010149598A2 (en) 2009-06-24 2010-12-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
ES2558554T3 (en) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Condensed tricyclic silyl compounds and methods of their use for the treatment of viral diseases
KR101899604B1 (en) 2010-05-02 2018-09-17 엑스제트 엘티디. Printing system with self-purge, sediment prevention and fumes removal arrangements
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
EP2621932A4 (en) * 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
EP2909209B1 (en) 2012-10-17 2022-08-03 Merck Sharp & Dohme LLC 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US9457039B2 (en) 2012-10-17 2016-10-04 Merck Sharp & Dohme Corp. 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AR092959A1 (en) 2012-10-17 2015-05-06 Merck Sharp & Dohme DERIVATIVES OF NUCLEOSIDS 2-METHYL SUBSTITUTED AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES
AU2013344757A1 (en) 2012-11-19 2015-05-21 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
US9765107B2 (en) 2013-06-18 2017-09-19 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2014205593A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
WO2014205592A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof for treatment of hepatitis c
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
WO2017223012A1 (en) 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
CN112898312B (en) * 2021-01-29 2021-11-12 湖南南新制药股份有限公司 Fused polycyclic pyridone derivative and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006034337A2 (en) * 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus
WO2007029029A2 (en) * 2005-09-09 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2007038209A2 (en) * 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006034337A2 (en) * 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus
WO2007029029A2 (en) * 2005-09-09 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2007038209A2 (en) * 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. SILVESTRI ET AL.: "Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737126", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 9, no. 2, 1998, pages 139 - 148, XP002523406 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063072B2 (en) 2009-09-21 2011-11-22 Roche Palo Alto Llc Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
ZA201001391B (en) 2010-11-24
TW200918536A (en) 2009-05-01
KR20100061819A (en) 2010-06-09
MX2010002316A (en) 2010-03-22
AU2008295483A1 (en) 2009-03-12
CA2697451A1 (en) 2009-03-12
AR068109A1 (en) 2009-11-04
CN101842376A (en) 2010-09-22
AU2008295483B2 (en) 2013-11-21
WO2009032123A2 (en) 2009-03-12
JP5179585B2 (en) 2013-04-10
JP2010537980A (en) 2010-12-09
EP2197884A2 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
WO2009032123A3 (en) Tetracyclic indole derivatives and their use for treating or preventing viral infections
MX2010002317A (en) Substituted indole derivatives and methods of use thereof.
MX2010002319A (en) 2, 3-substituted indole derivatives for treating viral infections.
MX2010005356A (en) 3-heterocyclic substituted indole derivatives and methods of use thereof.
MX2010002318A (en) 2,3-substituted azaindole derivatives for treating viral infections.
MX2010005355A (en) 3-aminosulfonyl substituted indole derivatives and methods of use thereof.
WO2008136815A3 (en) 5, 6-ring annulated indole derivatives and use thereof
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008115281A3 (en) Compounds for treating viral infections
WO2010062821A8 (en) Anti-viral compounds, compositions, and methods of use
WO2010014134A8 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
IL250858A0 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
MX2009011533A (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases.
IL187135A0 (en) 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
WO2009129246A3 (en) Compositions and methods for preparing and using same
MX2012011222A (en) Compounds and pharmaceutical compositions for the treatment of viral infections.
WO2009105513A3 (en) Novel compounds and methods for therapy
WO2009149179A3 (en) Enhanced antiviral therapy methods and devices
WO2011049988A3 (en) Indazoles to treat flaviviridae virus infection
WO2011158039A8 (en) Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (rsv) infection
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2008017346A3 (en) Ascorbic acid derivatives, use thereof for the functionalization of matrices
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113543.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795628

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 583388

Country of ref document: NZ

Ref document number: 2008295483

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 204053

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12010500407

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2697451

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010522933

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/002316

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008295483

Country of ref document: AU

Date of ref document: 20080827

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010000803

Country of ref document: MY

ENP Entry into the national phase

Ref document number: 20107006704

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008795628

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12675277

Country of ref document: US